Tasonermin - Genentech/Boehringer Ingelheim

Drug Profile

Tasonermin - Genentech/Boehringer Ingelheim

Alternative Names: Beromun; FK 516; TNF alpha - Genentech/Boehringer Ingelheim; TNF alpha-1a - Genentech/Boehringer Ingelheim; Tumour necrosis factor alpha - Genentech/Boehringer Ingelheim

Latest Information Update: 11 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Developer Amarillo Biosciences; Asahi Kasei; Genentech; Hayashibara
  • Class Antineoplastics; Blood proteins; Glycoproteins; Monokines; Tumour necrosis factors
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Sarcoma
  • Preregistration Submission Withdrawal Cancer
  • No development reported Viral infections

Most Recent Events

  • 11 Jun 2015 Launched for Sarcoma in Latvia, Lithuania, Luxembourg, Slovakia, Croatia, Estonia, Austria, Finland, France, Hungary, Malta, Romania and Slovenia (IV) before June 2015
  • 04 Oct 2001 A preclinical study has been added to the Cancer pharmacodynamics section
  • 20 Jan 2000 Mochida has withdrawn the NDA for TNFα in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top